Lipoprotein(a) in Residual Cardiovascular Risk: Measurement Challenges, Assay Standardisation, and Clinical Implications
Yiwen Lu, Dongyang Jiang, Jinfeng Zhang, Ying Liang · 2026
Read Lipoprotein(a) in Residual Cardiovascular Risk: Measurement Challenges, Assay Standardisation, and Clinical Implications by Yiwen Lu, Dongyang Jiang, Jinfeng Zhang, Ying Liang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13245467.txt.
Description
Yiwen Lu and co-authors explain why a blood fat called lipoprotein(a) is so hard to measure fairly in a 2026 review. Levels of this particle are set mostly by genes and raise heart risk on their own. Yet its odd structure fools common lab tests.
Copies of one protein segment vary by person, which skews tests that count by weight. The review favors reporting in moles, the count of particles, and warns against fixed swaps between units. High levels can also inflate standard cholesterol scores and mislead risk calls. Automated tests suit screening, while lab-grade methods anchor accuracy. Fair measurement matters more as drugs aimed at this particle near the clinic.
Catalog record
| CREATOR | Yiwen Lu, Dongyang Jiang, Jinfeng Zhang, Ying Liang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |